Susmed Inc
TSE:4263
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ashoka Buildcon Ltd
NSE:ASHOKA
|
IN |
Susmed Inc
EPS (Diluted)
Susmed Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Susmed Inc
TSE:4263
|
EPS (Diluted)
-¥17
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
M3 Inc
TSE:2413
|
EPS (Diluted)
¥73
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
S
|
Software Service Inc
TSE:3733
|
EPS (Diluted)
¥1.1k
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Medley Inc
TSE:4480
|
EPS (Diluted)
¥30
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Medical Data Vision Co Ltd
TSE:3902
|
EPS (Diluted)
¥7
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
6%
|
|
|
JMDC Inc
TSE:4483
|
EPS (Diluted)
¥125
|
CAGR 3-Years
31%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
Susmed Inc
Glance View
SUSMED, Inc. engages in the development of medical equipment and software systems. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2021-12-24. The firm operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.
See Also
What is Susmed Inc's EPS (Diluted)?
EPS (Diluted)
-17.8
JPY
Based on the financial report for Jun 30, 2025, Susmed Inc's EPS (Diluted) amounts to -17.8 JPY.
What is Susmed Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-23%
Over the last year, the EPS (Diluted) growth was 17%. The average annual EPS (Diluted) growth rates for Susmed Inc have been -7% over the past three years , -23% over the past five years .
